Home
GeniusMed

Global Major Partnership Network

Partners

R&D, marketing and sales collaboration with partners across 10+ countries including Korea, Japan, China, Switzerland and Singapore.

10+

Countries

12+

Global Partners

R&D · Marketing · Sales

Category

CH CSEM SA KR GeniusMed HQ JP IT Lab · OfficeHase CN Shanghai Upper Bio-Tech SG Everlife

Partners

Global Major Partner Network

CH R&D

CSEM SA

Switzerland

A non-profit research and technology organisation founded by the Swiss federal government in 1984. Anchored by its Neuchâtel headquarters, around 640 researchers from 45 countries lead in ultra-low-power chips, biosensors and wearable vital-sign monitoring.

www.csem.ch
JP R&D

IT Lab Co., Ltd.

Japan

Development partner for in-vitro diagnostic devices and biopharmaceuticals.

JP Marketing

OfficeHase Co., Ltd.

Japan

Marketing partner for the Japanese market.

CN R&D · Marketing

Shanghai Upper Bio-Tech Pharma

China

IVD medical device developer and China marketing partner. Listed on the Beijing Stock Exchange.

SG Marketing

Everlife Co., Ltd.

Singapore

ASEAN (Southeast Asia) & India marketing partner.

KR R&D · Sales

Seegene Co., Ltd.

Korea

Partner for IVD medical device development and sales.

Global R&D Collaboration

CSEM MoU & Eurostars joint proposal

A memorandum of understanding with Switzerland's CSEM was signed electronically on 2 July 2026 and is valid for two years. The parties jointly develop vital-sign monitoring — heart rate, HRV, SpO₂, blood pressure and EEG — integrated into smart glasses. GeniusMed leads the project and system integration; CSEM contributes optical sensing, biopotentials and digital-health R&D.

A joint proposal for the Eurostars call is being prepared with CSEM. If selected, the Korean SME is funded for up to 67% of project cost through the Korea Institute for Advancement of Technology, strengthening eligibility for global government R&D funding.

CEO Brian Lee · Jens Krauss (VP MedTech BU, CSEM)

CSEM Profile

Founded
1984
Researchers
640+
Countries
45
Headquarters
Neuchâtel, CH
MoU signed
2026.07.02
Validity
2 years